A combination of eyelid pressure patching and decellularized, dehydrated pure amniotic membrane basement membrane healed ...

Design Therapeutics, Inc., a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m ...